A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
- PMID: 9728532
- DOI: 10.1086/515386
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
Erratum in
- J Infect Dis 1998 Nov;178(5):1553
Abstract
The Zaire subtype of Ebola virus (EBO-Z) is lethal for newborn mice, but adult mice are resistant to the virus, which prevents their use as an animal model of lethal Ebola infection. We serially passed EBO-Z virus in progressively older suckling mice, eventually obtaining a plaque-purified virus that was lethal for mature, immunocompetent BALB/c and C57BL/6 inbred and ICR (CD-1) outbred mice. Pathologic changes in the liver and spleen of infected mice resembled those in EBO-Z-infected primates. Virus titers in these tissues reached 10(9) pfu/g. The LD50 of mouse-adapted EBO-Z virus inoculated into the peritoneal cavity was approximately 1 virion. Mice were resistant to large doses of the same virus inoculated subcutaneously, intradermally, or intramuscularly. Mice injected peripherally with mouse-adapted or intraperitoneally with non-adapted EBO-Z virus resisted subsequent challenge with mouse-adapted virus.
Similar articles
-
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.J Infect Dis. 1999 Feb;179 Suppl 1:S248-58. doi: 10.1086/514292. J Infect Dis. 1999. PMID: 9988191
-
Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice.J Comp Pathol. 2001 Nov;125(4):233-42. doi: 10.1053/jcpa.2001.0502. J Comp Pathol. 2001. PMID: 11798240
-
Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells.J Virol. 2002 Sep;76(18):9176-85. doi: 10.1128/jvi.76.18.9176-9185.2002. J Virol. 2002. PMID: 12186901 Free PMC article.
-
[Properties of the Ebola virus glycoprotein].Uirusu. 2006 Jun;56(1):117-24. doi: 10.2222/jsv.56.117. Uirusu. 2006. PMID: 17038820 Review. Japanese.
-
Immunopathology of highly virulent pathogens: insights from Ebola virus.Nat Immunol. 2007 Nov;8(11):1159-64. doi: 10.1038/ni1519. Nat Immunol. 2007. PMID: 17952040 Free PMC article. Review.
Cited by
-
A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20695-700. doi: 10.1073/pnas.1117715108. Epub 2011 Dec 5. Proc Natl Acad Sci U S A. 2011. PMID: 22143779 Free PMC article.
-
Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers.Viruses. 2012 Dec 14;4(12):3754-84. doi: 10.3390/v4123754. Viruses. 2012. PMID: 23242370 Free PMC article. Review.
-
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.Sci Transl Med. 2013 Jun 19;5(190):190ra79. doi: 10.1126/scitranslmed.3005471. Sci Transl Med. 2013. PMID: 23785035 Free PMC article.
-
Molecular mechanisms of Ebola pathogenesis.J Leukoc Biol. 2016 Nov;100(5):889-904. doi: 10.1189/jlb.4RI0316-099RR. Epub 2016 Sep 1. J Leukoc Biol. 2016. PMID: 27587404 Free PMC article. Review.
-
A thermostable, chromatographically purified Ebola nano-VLP vaccine.J Transl Med. 2015 Jul 15;13:228. doi: 10.1186/s12967-015-0593-y. J Transl Med. 2015. PMID: 26174690 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical